MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Agios Pharmaceuticals Total Assets 2011-2026 | AGIO
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Agios Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.3 B | 1.66 B | 937 M | 1.24 B | 1.44 B | 853 M | 891 M | 858 M | 614 M | 619 M | 420 M | 492 M | 201 M | 137 M | 194 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.66 B | 137 M | 790 M |
Quarterly Total Assets Agios Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.47 B | 1.56 B | 1.66 B | 1.79 B | 773 M | 850 M | 937 M | 1.01 B | 1.09 B | 1.15 B | 1.24 B | 1.18 B | - | 1.34 B | 1.44 B | 1.54 B | 1.87 B | 2.49 B | 853 M | 853 M | 853 M | 853 M | 891 M | 891 M | 891 M | 891 M | 858 M | 858 M | 858 M | 858 M | 614 M | 614 M | 614 M | 614 M | 619 M | 619 M | 619 M | 619 M | 420 M | 420 M | 420 M | 420 M | 492 M | 492 M | 492 M | 492 M | 201 M | 201 M | 201 M | 201 M | 137 M | 137 M | 137 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.49 B | 137 M | 838 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burford Capital Limited
BUR
|
3.11 B | $ 4.74 | 0.53 % | $ 761 M |  Britain |
 |
Cabaletta Bio
CABA
|
165 M | $ 3.33 | 2.15 % | $ 335 M |  USA |
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.51 M | $ 3.07 | 0.49 % | $ 5.05 M |  Israel |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
4.97 B | $ 332.58 | -2.01 % | $ 43.6 B | USA |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.8 | 4.97 % | $ 9.14 B |  Australia |
 |
AlloVir
ALVR
|
122 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
88.5 M | $ 7.51 | -14.07 % | $ 74.2 M | USA |
 |
Allakos
ALLK
|
244 M | - | - | $ 28.6 M | USA |
 |
Esperion Therapeutics
ESPR
|
466 M | $ 2.11 | 2.77 % | $ 439 M | USA |
 |
Evogene Ltd.
EVGN
|
20 M | $ 0.82 | - | $ 27.9 M | Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
|
Forte Biosciences
FBRX
|
82.8 M | $ 32.35 | -0.2 % | $ 419 M | USA |
 |
Midatech Pharma plc
MTP
|
18.2 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
54.8 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
62.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Galapagos NV
GLPG
|
3.41 B | $ 28.99 | 0.36 % | $ 2.69 B |  Belgium |
 |
Amphastar Pharmaceuticals
AMPH
|
1.63 B | $ 21.36 | -0.09 % | $ 998 M | USA |
 |
Genmab A/S
GMAB
|
21.1 B | $ 29.02 | -0.14 % | $ 18.6 B |  Danmark |
 |
GT Biopharma
GTBP
|
8.11 M | $ 0.38 | -3.34 % | $ 2.1 M | USA |
 |
BioNTech SE
BNTX
|
22 B | $ 99.43 | 1.03 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Hoth Therapeutics
HOTH
|
7.6 M | $ 0.68 | 4.58 % | $ 9.39 M | USA |
 |
Aeterna Zentaris
AEZS
|
21.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
Harmony Biosciences Holdings
HRMY
|
1.27 B | $ 29.37 | 0.27 % | $ 1.69 B | USA |
 |
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K | USA |
 |
ImmuCell Corporation
ICCC
|
42.5 M | $ 7.61 | -1.55 % | $ 68.7 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
377 M | $ 1.54 | -1.28 % | $ 396 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
160 M | $ 4.18 | 0.6 % | $ 447 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
433 M | $ 24.39 | -2.79 % | $ 3.1 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
1.02 M | - | -2.5 % | $ 5.88 M | USA |
 |
AIkido Pharma
AIKI
|
113 M | - | 1.93 % | $ 17.4 M | USA |
 |
Incyte Corporation
INCY
|
6.96 B | $ 97.43 | -0.27 % | $ 19 B | USA |
 |
BioDelivery Sciences International
BDSI
|
325 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
589 M | $ 1.46 | -1.49 % | $ 389 M | Britain |
 |
Aptose Biosciences
APTO
|
10 M | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
8.19 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Innate Pharma S.A.
IPHA
|
62.7 M | $ 1.71 | 4.91 % | $ 235 M | France |